TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00825539
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01777165
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo infusion
Study: NCT00742105
Drug: BGT226
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00239785
Drug: FTY720
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00154687
Drug: Paclitaxel, Cisplatin, 5-Fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01948362
Drug: Sulforadex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active compound
Study: NCT02463045
Drug: TOP1288
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03335436
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive Placebo with similar appearance to gabapentin by mouth one hour prior to scheduled cesarean delivery and by mouth every 8 hours post delivery
Study: NCT04301895
Drug: Remifentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 minute remifentanil infusion
Study: NCT01441635
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablets
Study: NCT01441635
Drug: Estradiol/Norethindrone acetate (E2/NETA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A continuous once-daily oral tablet containing estrogen and progestin; the low-dose strength contains estradiol 0.5 mg and norethindrone acetate 0.1 mg.
Study: NCT01441635
Drug: Estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1.0 mg micronized estradiol tablets administered once a day
Study: NCT02683785
Drug: GSK3196165
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3196165 will be supplied as a liquid and will be administered as a subcutaneous injection. The drug will be administered weekly for 5 injections, then every other week for 3 further injections.
Study: NCT02683785
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo will be administered as above.
Study: NCT02299947
Drug: Haemocomplettan P
Normalized name: P & S
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02299947
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02489240
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2000 IU placebo tablets were taken daily for 6 days
Study: NCT02713477
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: solution~Route of administration: subcutaneous
Study: NCT00759772
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: sc daily for 6 months
Study: NCT02866032
Drug: MOB015B
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01305408
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablets, taken orally, once daily in the morning
Study: NCT00600743
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug one trial vs placebo
Study: NCT04299633
Drug: Calcium acetate
Normalized name: Calcium Acetate
DrugBank: Calcium sulfate (DB15533)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 x 667 mg oral gelcaps
Study: NCT04299633
Drug: Auryxia®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 x 1 gram tablets (210 mg ferric iron equivalent to 1000 mg ferric citrate)
Study: NCT02869113
Drug: BAY 98751 (Y65-102)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 µL in one eye
Study: NCT02869113
Drug: BAY 98751 (Y65-106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 µL in one eye
Study: NCT02869113
Drug: Standard shampoo mixture (Control)
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 µL in other eye
Study: NCT00842244
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given orally twice daily for 14 days followed by 7 days of drug free period. Starting dose is 1000mg/m\^2 twice daily. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.
Study: NCT05015673
Drug: SEP363856
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05015673
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02084199
Drug: GLPG0634
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg oral tablet, intake once daily for 10 days
Study: NCT01436253
Drug: Hypolipemics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological measures at the discretion of the treating physician and in accordance with the respective authorized label and European Guidelines on the Management of Hypercholesterolemia accepted by the Croatian Society of Cardiology.
Study: NCT01406470
Drug: Immune Globulin Intravenous (Human) 5% Liquid, IVIG-SN™
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIG-SN™ 10g/200mL, dose is 300-900 mg/kg/infusion every 21 or 28 days, intravenously. The total duration of treatment with IVIG-SN™ will be 12 months with a 3 month follow-up.
Study: NCT00825149
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide will be administered as per schedule specified in the respective arm.
Study: NCT00825149
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin will be administered as per schedule specified in the respective arm.
Study: NCT00413205
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: po daily
Study: NCT00623805
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine was supplied as film-coated tablets.
Study: NCT04536129
Drug: Hydrocortisone (CORTIVIS ®)
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Once enrolled all the patients had to instill topical low dose (1,005 mg) preservative-free hydrocortisone (CORTIVIS ®- Medivis, Catania, Italy) 2 times daily in each eye for two weeks.
Study: NCT01200290
Drug: LY2127399
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 milligrams (mg) administered subcutaneously every 4 weeks for 20 weeks. A loading dose of 240 mg will be given as the first dose of the study medication
Study: NCT01144377
Drug: LY2541546
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously
Study: NCT01144377
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously
Study: NCT00925678
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00099749
Drug: FTY 720
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01304082
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ml subcutaneous injection 0.9% sodium chloride, given once
Study: NCT02397460
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03848039
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: administration by intramuscular injection of the placebo according to vaccination schedule of the 9-valent HPV vaccine (0, 2, 6 months)
Study: NCT02213055
Drug: Standard Head lice product
Normalized name: Head & Shoulders Shampoo Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: The most common treatments are pesticide-based, over-the-counter remedies of permethrin (1%), or pyrethrin-based products.After baseline scalp exam for lice count and preexisting signs of irritation, parents who agree to the comparison arm may purchase any other head lice treatment of their choice. All treatments are to be done at home by a parent or guardian. All participants will be examined for lice count and scalp irritation the day after the first application, and one and two weeks after the first application. Participants may also be examined by parents or the school nurse at any time if signs of irritation or re-infestation occur. If the child is still found to be infested during any examination, the school nurse will instruct the parent/guardian to retreat.
Study: NCT00999973
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01907776
Drug: ME1100 inhalation solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: ME1100 inhalation solution (arbekacin for oral inhalation at 150mg/mL), 0.6, 2.0, 3.0, 4.0, 6.0, or 9.0mL, Single Dose
Study: NCT01907776
Drug: ME1100 placebo inhalation solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle placebo
Study: NCT02671760
Drug: Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-drug combination comprised of 5 mg zolpidem and 0.5 mg lorazepam
Study: NCT02671760
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02191384
Drug: Orcinoside
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral, twice per day
Study: NCT03349619
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in this arm will receive nasal saline solution 0.9%, two sprays per nostril, three times/day for 4 weeks
Study: NCT01556763
Drug: EVP-6124 (0.3 mg/day)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EVP-6124 was administered as one 0.3 mg capsule per day for 21 days.
Study: NCT01556763
Drug: EVP-6124 (1.0 mg/day)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EVP-6124 was administered as one 1.0 mg capsule per day for 21 days.
Study: NCT01556763
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo was administered as one capsule per day for 21 days.
Study: NCT01556763
Drug: Antipsychotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant therapy with antipsychotic medication (aripiprazole \[10 to 30 mg/day\], olanzapine \[10 to 20 mg/day\], paliperidone \[3 to 12 mg/day\], or risperidone \[2 to 16 mg/day\]), taken at the same time each day as the EVP-6124 dose. Patients must have been taking concomitant therapy for at least 2 weeks at a stable dose to be eligible for the study.
Study: NCT00132899
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate and infliximab combination
Study: NCT00132899
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo and infliximab combination therapy.
Study: NCT00159263
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dry powder inhaler
Study: NCT00174694
Drug: Telithromycin
Normalized name: Telithromycin
DrugBank: Telithromycin (DB00976)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00570284
Drug: LBH589
Approvals — FDA: no, EMA: no, PMDA: no
Description: orally administered panobinostat at 20 mg twice weekly (core phase); orally administered panobinostat 45 mg twice weekly if 20 mg twice weekly was tolerated in Cycle 1 (extension phase)
Study: NCT00088933
Drug: recombinant fowlpox-CEA(6D)/TRICOM vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given intradermally
Study: NCT00918879
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet, once daily for 24 weeks
Study: NCT01205022
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01205022
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01431820
Drug: Vehicle Solution
Normalized name: compounding vehicle solution sugar free no. 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical
Study: NCT00138229
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00565812
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets once a day for 2 years
Study: NCT00865111
Drug: Wellbutrin SR® 150 mg Sustained-Release Tablet, single dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: B: Active comparator Subjects received GlaxoSmithKline formulated products under fasting conditions
Study: NCT04374500
Drug: Vasodilators in CAD patients
Approvals — FDA: no, EMA: no, PMDA: no
Description: This applies only to protocol 3
Study: NCT02426112
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02426112
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04441424
Drug: Hydroxychloroquin with Azithromycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: The control group of COVID-19 patients were given the conventional therapy approved in Iraq for COVID-19, namely Hydroxychloroquine 400mg PO twice per day for 5 days and Azithromycin once PO 500 mg per day for 5 days.
Study: NCT03854812
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: loading of 1 mcg/kg in over 15 minutes of fentanyl then will receive continuous infusion starting at 1 ml /kg/h. of 0.5 mcg/ml solution
Study: NCT00666900
Drug: Low Strength IDP-107
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once a day for 12 weeks
Study: NCT00666900
Drug: Placebo Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once a day for 12 weeks
Study: NCT00601263
Drug: Anti-Asthma Herbal Medical Intervention (ASHMI)
Normalized name: pramoxine hydrochloride Medicated Pad [Scalpicin Anti-Itch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: We propose to test 3 daily doses in which 2,4, or 6 ASHMI or placebo capsules will be administered orally twice daily (BID) for 7 days.
Study: NCT00234702
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01225276
Drug: NewGam 10%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading dose at baseline (Week 0) will be 2.0 g/kg NewGam . The maintenance doses to be infused 7 times will be 2.0 g/kg every 21 (+/-4) days.
Study: NCT01225276
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading dose at baseline (Week 0) in Placebo arm will be corresponding volume of an authorised 0.9% saline solution . The maintenance doses of the 0.9% saline solution to be infused 7 times will be given every 21 (+/-4) days.
Study: NCT01225276
Drug: NewGam 10%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading dose at baseline (Week 0) will be 2.0 g/kg NewGam in all three NewGam treatment arms. The maintenance doses to be infused 7 times will be 1.0 g/kg every 21 (+/-4) days.
Study: NCT01365936
Drug: HMG
Normalized name: HMG-CoA reductase
Approvals — FDA: no, EMA: no, PMDA: no
Description: In this prospective trial, women with PCOS (according to Rotterdam criteria) were randomized (80 patients) after GnRH analogue suppression to stimulation with HMG (n=38) or rFSH (n=42) using a low dose step up protocol in ICSI cycles.
Study: NCT01225276
Drug: NewGam 10%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading dose at baseline (Week 0) will be 2.0 g/kg NewGam in all three NewGam treatment arms. The maintenance doses to be infused 7 times will be 0.4 g/kg every 21 (+/-4) days.
Study: NCT01228318
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1. A single dose of reclast containing 5 mg/100 mL ready-to-infuse zoledronic acid solution administered over 15-30 minutes.~2. A single dose of placebo containing 220 mg mannitol and 24 mg sodium citrate in a 100 mL ready-to-infuse solution, administered over 15-30 minutes.
Study: NCT03867695
Drug: sterile saline
Normalized name: Aqua Care Sterile Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive a placebo injection with 0,5 mL/kg of sterile normal solution
Study: NCT04393194
Drug: Vaginal Cream with Applicator [Dose Form]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with symptomatic POP will be assigned as outpatients. After the initial pessary fitting, the patients will be followed up in 2 weeks. If the prolapse is supported, no discomfort, and the patient decides to continue to use the pessary, the pessary fitting is successful. Patients with successful ring pessary fitting, who agree to participate and sign written consent, will be randomized into the vaginal estrogen group and the placebo group. The patients will be followed up every 3 months after wearing pessary combined with vaginal medication, until 1 year after wearing the pessary.
Study: NCT03011567
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive acetaminophen for postpartum mild pain relief
Study: NCT03011567
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive ibuprofen for postpartum mild pain relief
Study: NCT00603525
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mL sterile, pyrogen free 0.9% NaCl. A treatment cycle consisting of two IV infusion taken 14 days apart. Only one placebo treatment cycle provided over a 24 week period
Study: NCT02686177
Drug: Metformin or sulfonylurea
Normalized name: metformin and sulfonylureas
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00218114
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be on matching placebo.
Study: NCT03561298
Drug: BGB-3111 and Drug Cocktail
Normalized name: BLOOD AND BLOOD FORMING ORGAN DRUGS
Approvals — FDA: no, EMA: no, PMDA: no
Description: BGB-3111 and Drug Cocktail (midazolam, warfarin, omeprazole, digoxin and rosuvastatin)
Study: NCT01784120
Drug: Doxorubicin/Genexol-PM
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00615875
Drug: naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: opaque pale orange suspension: 20mL q12h x 4 doses mixed in juice.
Study: NCT00615875
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: opaque pale orange suspension: 20mL q12h x 4 doses mixed in juice
Study: NCT01941173
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01941173
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00128245
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02513992
Drug: 99m-Technetium Ethyl Cysteinate Dimer
Approvals — FDA: no, EMA: no, PMDA: no
Description: administration of perfusion tracer 99m Tc-ECD during epileptic seizure
Study: NCT00219700
Drug: Ibuprofen-PC
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04371666
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo per schedule specified in the arm description
Study: NCT03433677
Drug: LY900014
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by CSII
Study: NCT00750295
Drug: SBR759
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four weeks of treatment with different doses of SBR759. Patients maintain their prescribed dose of other phosphate binders during the run-in period.
Study: NCT04371666
Drug: Corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic deflazacort or equivalent potency of corticosteroids administered orally
Study: NCT02330419
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04348786
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycylcine 100 mg bid ,esomprazole 20 bid,Bismuth subsalicylate 262 tab.2 tab q.i.d,Tinadizole 500 bid
Study: NCT01041404
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 800 mg/m2 i.v. infusion on Days 1 through 5 of cycle every 3 weeks for 6 cycles
Study: NCT01041404
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000 mg/m2 p.o. twice daily on Days 1 through 15 of cycle every 3 weeks for 6 cycles
Study: NCT02750449
Drug: Sun screening Sport Lotion, (BAY987516)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 μl/ cm\*2 of the test article is applied directly to two sites on the skin and covered with the appropriate patch. 24 hours later, the patches are removed. The test sites are lightly wiped with a dry cloth/tissue and 3 μl/ cm\*2 of test article is reapplied directly to the skin of the test site designated for irradiation, and lightly spread over the test site. 48 hours later the procedure is repeated to the same test sites. This process is repeated twice weekly for a total of six exposures. (Formulation Number - RB# Y65-110)
Study: NCT00785811
Drug: Placebo L-arginine aspartate (Targifor)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo of L-arginine taken orally in a single daily dose for 8 weeks
Study: NCT02936843
Drug: Salsalate
Normalized name: Salsalate
DrugBank: Salsalate (DB01399)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 gram, 3 times daily by mouth (total of 3 grams daily)
Study: NCT02936843
Drug: PLACEBO
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for Salsalate; 2 Tabets, 3 times daily by mouth (total of 3 grams daily)
Study: NCT01025830
Drug: Zerit/Epivir/Viramune
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stavudine (40mg) Lamivudine (150mg) and Nevirapine (200mg) All taken twice daily.
Study: NCT04411329
Drug: Hyalouridinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: hyalouridinase
Study: NCT03293524
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo is a BSS, sterile, apyrogenic solution and used for ocular surgery. The placebo will be administered via intravitreal injection in a volume of 90 μL.
Study: NCT00384189
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciclesonide placebo-matching inhaler
Study: NCT00280215
Drug: ACEI / Angiotensin converting enzyme inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be randomized to a combination of Angiotensin Converting Enzyme Inhibitor and Angiotensin Receptor Blocker, Patients will be randomized to a combination of ARB(losartan 50 mg daily in adult patients, 0.7 mg/kg/day in patients \< 40 kg) ACE-I (lisinopril 10 mg daily in adult patients, 0.15 mg/kg/day in pediatric patients \< 40 kg) to be taken for 24 months.
Study: NCT00534976
Drug: Comparator: Comparator: placebo (unspecified)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients 4-5 years: 4 mg Pbo chewable tablet daily~Patients 6-14 years: 5 mg Pbo chewable tablet daily
Study: NCT03724253
Drug: [68Ga]-NeoBOMB1
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[68Ga\]-radiolabeled bombesin peptide targeting Gastrin Releasing Peptide Receptors
Study: NCT00426127
Drug: Liposomal Doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03338296
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablet